Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Sunshine Biopharma Inc. (SBFM)

Sunshine Biopharma director Andrew Keller will not seek reelection to board

Neutral Impact 2 of 5 leadership Written later

Sunshine Biopharma director Dr. Andrew Keller notified the company on August 25, 2026, that he will not seek or accept reelection when his current term ends at the next annual shareholder meeting. The filing discloses no reason for the departure and no financial results, so it is a board-composition change with no stated direct financial effect.

Key points

  • Director Dr. Andrew Keller notified the company on August 25, 2026.
  • Keller will not seek or accept reelection when his current term expires.
  • His term ends at the company's next annual shareholder meeting.
  • The 8-K was signed by CEO Dr. Steve N. Slilaty on August 28, 2026.

The filing

CompanySunshine Biopharma Inc. (SBFM)
Form8-K, current report
Filed with the SECAug 28, 2026, 4:05 PM ET
Accession number0001683168-26-006777

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 28, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.